A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients.
Hattersley, Andrew T.
JournalDiabetic medicine : a journal of the British Diabetic Association
TypeResearch Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
RightsArchived with thanks to Diabetic medicine : a journal of the British Diabetic Association
MetadataShow full item record
Hepatocyte nuclear factor-1 alpha (HNF1A) gene mutations are the commonest cause of monogenic diabetes, but patients are often misdiagnosed as having Type 1 diabetes and started on insulin treatment. Patients with HNF1A diabetes are particularly sensitive to the glucose-lowering effect of sulphonylureas, which are the pharmacological treatment of choice. We aimed to assess if patients do change from insulin to sulphonylurea treatment when HNF1A diabetes is confirmed and the impact of this treatment change on long-term glycaemic control.